Frequency of Upper Airway Symptoms before and during Continuous Positive Airway Pressure Treatment in Patients with Obstructive Sleep Apnea Syndrome

Hanna-Riikka Kreivi, Paula Virkkula, Juho Lehto, Pirkko Brander

Division of Pulmonary Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, and Department of Pulmonary Diseases, Hospital District of Helsinki and Uusimaa, Hyvinkää Hospital, Hyvinkää, Finland

Introduction

Obstructive sleep apnea is a disorder characterized by excessive snoring and periodic breathing with repetitive apneas, hypopneas and arousals leading to fragmented sleep. The treatment of choice for the obstructive sleep apnea syndrome (OSAS) is nasal continuous positive airway pressure (nCPAP), which effectively eliminates apneas, hypopneas and snoring. Therefore, this treatment improves sleep quality and reduces excessive daytime sleepiness as well as other symptoms of OSAS [1–3].

Key Words
Continuous positive airway pressure • Upper airway symptoms • Obstructive sleep apnea syndrome

Abstract
Background: Upper airway side effects are common during nasal continuous positive airway pressure (nCPAP) treatment and may affect the use of nCPAP. Objectives: It was our aim to evaluate the prevalence of upper airway symptoms in obstructive sleep apnea syndrome (OSAS) patients before and during nCPAP treatment and to assess the possible association between the symptoms and long-term adherence to the treatment. Methods: We examined 385 consecutive OSAS patients (79% men, mean age ± SD 52 ± 10 years and apnea-hypopnea index 33 ± 23) by means of a prospective questionnaire-based survey. The patients filled in questionnaires about upper airway symptoms before starting nCPAP and after 2 months of treatment. Results: Upper airway symptoms were common before starting nCPAP: 61% of the patients reported dryness of mouth, 54% dryness of throat, 52% nasal stuffiness, 51% dryness of nose, 30% sneezing, 24% mucus in throat, 17% rhinorrhea, and 6% nose bleeds daily or almost daily. In CPAP users there was a significant decline in the number of patients with frequent mouth (37%), throat (34%), nose (28%) dryness and nasal stuffiness (24%). There was no difference in upper airway symptoms before nCPAP treatment between those who continued the treatment after 1 year and those who terminated the treatment. Conclusions: The most common upper airway symptoms in patients with untreated OSAS seem to be associated with mucosal dryness. These symptoms improved during nCPAP treatment probably due to the change in breathing pattern. The occurrence of upper airway symptoms before nCPAP start did not predict long-term adherence to the treatment.

Hanna-Riikka Kreivi, MD
Division of Pulmonary Diseases
Department of Medicine, Helsinki University Central Hospital
Haartmaninkatu 4, PO Box 340, FI-00290 Helsinki (Finland)
Tel. +358 9 4711, Fax +358 9 4717 4481, E-Mail hanna-riikka.kreivi@fimnet.fi
Upper airway side effects, which are often reported during nCPAP treatment, may cause substantial discomfort to the patients and even lead to treatment cessation despite improvements in OSAS symptoms [4–7]. These side effects have mostly been related to local irritation caused by the nasal masks and by mouth leaks that produce high unidirectional airflow over the nasal and oral mucosa. Nasal and pharyngeal side effects can be managed by mask optimization, by intranasal corticosteroid mucosa. Nasal and pharyngeal side effects can be managed by mask optimization, by intranasal corticosteroid therapy [8–10], by adding a humidifier to the treatment [9–11] or by corrective surgery for obstructive lesions (e.g., deviated septum) [12, 13].

Most of the reports about side effects are retrospective analyses and often lack baseline data [14]. Previous small-scale studies revealed that OSAS patients had suffered from nasal and pharyngeal problems even before treatment [4, 5] and that some of the symptoms became worse during treatment [4]. The present prospective study was carried out as part of the clinical follow-up of our sleep clinic patients in order to (1) evaluate upper airway symptoms in a large group of OSAS patients both before and during nCPAP treatment, and (2) analyze the relationship between nasal and pharyngeal symptoms and long-term adherence to the treatment.

**Patients and Methods**

All consecutive OSAS patients (n = 385) who were admitted to the sleep unit of Hyvinkää Hospital for nCPAP pressure titration from January 2003 to December 2004 were included in this study (table 1). The patients had earlier undergone a diagnostic limited sleep study (Emblettas®, Flaga, Reykjavik, Iceland). All the sleep recordings were analyzed manually [15] and the apnea/hypopnea index/hour and a reduction in oxygen saturation ≥ 4%/h were recorded. Apneas were defined as a complete cessation of airflow for ≥ 10 s, and hypopneas as a decrease of ≥ 50% in the amplitude of breathing for ≥ 10 s that was associated with an oxygen desaturation of ≥ 3% [16]. nCPAP treatment was started during 1 night in the sleep clinic using an autotitrating CPAP device (Autotitr®, Resmed, Sydney, NSW, Australia); the fixed treatment pressure chosen was the pressure eliminating 95% of obstructive apneas and hypopneas, snoring and flow limitation. The nasal masks were individually adjusted to minimize discomfort related to their use. Full face masks were used if nasal masks were not tolerated. All patients were given detailed instructions on nCPAP treatment and its possible side effects. The patients were advised how to treat nasal and pharyngeal symptoms with topical medications (oily or saline nasal drops, as well as temporary use of nasal decongestants during viral infections), and all were given a prescription of intranasal steroids with the advice to purchase the medication from a pharmacy and to start the treatment if nasal symptoms became problematic during nCPAP treatment. Humidifiers were added to the treatment only if local treatment was not sufficiently effective (not before the first follow-up visit after 2 months of treatment).

All the patients filled in 2 questionnaires on nasal and pharyngeal history and current symptoms. The symptoms were scored (1) in the evening before nCPAP pressure titration, and (2) at the first follow-up visit after 2 months of treatment. All the patients were examined by a physician (specialist in pulmonary medicine), and careful ear, nose and throat (ENT) status was routinely included in the physical examination. If there were major anatomical problems, the patients were referred to an ENT specialist before starting nCPAP. Their Epworth sleepiness scale score [17] was assessed, and weight and body mass index were measured at baseline and at follow-up visits. At the follow-up visits, hours of nCPAP use were recorded from the timers incorporated into the devices. The time of the year was registered both at CPAP initiation and at follow-up visits. The study was approved by the local ethics committee.

**Questionnaires**

The questionnaire comprised 2 sections: (1) history of nasal and pharyngeal disorders, operations, allergic rhinitis and medications, and (2) current upper airway symptoms (nasal stuffiness, dryness of throat, mouth and nose, sensation of mucus in throat, sneezing, rhinorrhea and nose bleeds). At follow-up visits, the patients filled in another questionnaire asking the same questions about upper airway symptoms occurring during nCPAP treatment. The frequency of symptoms was evaluated by asking how often the symptom was experienced using a scale of 1–4 (1 = never; 2 = occasionally; 3 = often, i.e. almost every day; 4 = all the time, i.e. every day). Scores 3 and 4 were combined and represented frequent symptoms in the final analysis. At the follow-up visits, the patients were asked if they experienced a benefit from the treatment. They were also asked whether nasal symptoms were the reason for stopping the treatment.

**Statistical Analysis**

An independent samples t test, $\chi^2$ test and Mann-Whitney U statistics were used to compare differences between separate patient groups. The difference in the number of symptomatic patients before and during nCPAP treatment was tested with McNemar’s test. All statistical analyses used SPSS 15.0 for Microsoft Windows (SPSS Inc. Chicago, Ill., USA). $p$ values <0.05 were considered significant.
Results

Adherence to nCPAP Treatment

After pressure titration, 370 patients (96%) initiated nCPAP treatment. The treatment was abandoned by 82 (22%) patients before or at the first follow-up visit, and by another 51 (14%) patients during the first year. Thus, 237 patients (64%) were continuing with the treatment after the first year (fig. 1).

At the first follow-up visit, mean (± SD) hours of use were 3.2 ± 2.6 h/day, and 52% of the patients were using nCPAP for >4 h/day. At 1-year follow-up, the mean use was 3.9 ± 2.4 h/day, with 58% of the patients using nCPAP >4 h/day. Both at 2-month and 1-year follow-up, the patients who chose to continue nCPAP (‘users’) showed a significantly higher rate of use than those who terminated the treatment after that follow-up (‘non-users’) (table 2). The users were more obese at baseline than the non-users, and their sleep apnea was more severe (table 2). Further, the users more often gained benefit from the treatment than non-users (after 2 months, 84 vs. 9%, p < 0.001; after 1 year, 96 vs. 5%, p < 0.001).

Frequency of Upper Airway Symptoms before and during nCPAP Treatment

Upper airway history and treatments before nCPAP start are shown in table 3. The prevalence of frequent nasal and pharyngeal symptoms before nCPAP treatment and at the 1st follow-up visit is depicted in figure 2. The symptoms were common already before starting nCPAP treatment and exhibited no increase during therapy in the overall patient group. On the contrary, the patients reported less dryness of mouth, throat, and nose after 2 months of treatment. Only 36 patients did not have any of the upper airway symptoms before nCPAP treatment. Altogether, 142 patients (37%) had no throat dryness before the treatment, and of those, 38 patients (22%) had throat dryness at the 2-month follow-up; 119 patients (31%) had no mouth dryness before the treatment, and of

Table 2. nCPAP users1 and non-users2 at 2-month and 1-year follow-up visits

<table>
<thead>
<tr>
<th></th>
<th>2-month follow-up visit</th>
<th></th>
<th>1-year follow-up visit</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>users (n = 288)</td>
<td>non-users (n = 82)</td>
<td>p</td>
<td>users (n = 237)</td>
</tr>
<tr>
<td>BMI (baseline)</td>
<td>34 ± 7</td>
<td>31 ± 5</td>
<td>&lt;0.01</td>
<td>34 ± 7</td>
</tr>
<tr>
<td>ESS (baseline)</td>
<td>9 ± 4</td>
<td>8 ± 4</td>
<td>NS</td>
<td>9 ± 4</td>
</tr>
<tr>
<td>AHI (baseline)</td>
<td>35 ± 24</td>
<td>26 ± 21</td>
<td>&lt;0.01</td>
<td>36 ± 25</td>
</tr>
<tr>
<td>ODI4 (baseline)</td>
<td>34 ± 24</td>
<td>26 ± 24</td>
<td>&lt;0.05</td>
<td>36 ± 25</td>
</tr>
<tr>
<td>CPAP pressure, cm H2O</td>
<td>9 ± 2</td>
<td>8 ± 2</td>
<td>NS</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>CPAP use, h/day</td>
<td>4.5 ± 2.3</td>
<td>1.0 ± 0.7</td>
<td>&lt;0.01</td>
<td>4.5 ± 2.2</td>
</tr>
</tbody>
</table>

Data presented as the mean ± SD. BMI = Body mass index; ESS = Epworth sleepiness scale (0–24); NS = not significant; AHI = apnea/hypopnea index; ODI4 = oxygen desaturation index.

1 Users = patients who continued the nasal CPAP treatment after that follow-up visit.
2 Non-users = patients who terminated the nasal CPAP treatment before or at the follow-up visit.

Fig. 1. The number of patients starting and continuing nCPAP treatment at 2-month and 1-year follow-up visits.
those, 28 patients (19%) had the symptom at follow-up; 142 patients (37%) had no nose dryness before the treatment, and of those, 43 patients (24%) had the symptom at follow-up; 293 patients (76%) had no nose bleeds before nCPAP, and of those, 16 patients (5%) had the symptom at follow-up; 146 patients (38%) had no nasal stuffiness before nCPAP, and of those, 52 patients (29%) had the symptom at follow-up; 256 patients (66%) had no rhinorrhea before the treatment, and of those, 37 patients (12%) had the symptom at follow-up; 229 patients (59%) had no postnasal drip before the treatment, and of those, 32 patients (12%) had the symptom at follow-up; and 212 patients (55%) had no sneezing before the treatment, and of those, 42 patients (16%) had the symptom at follow-up. Before the treatment, there was no difference in the extent of symptoms between the patients who continued nCPAP after 1 year (‘users after 1st year’) and the patients who terminated nCPAP treatment (‘non-users’) (table 4). After 2 months of treatment, rhinorrhea increased significantly in non-users, but symptoms of upper airway dryness did not change (table 4), whereas in nCPAP users, there was a significant decline in the number of patients with frequent mouth (37%), throat (34%) and nose (28%)
dryness and nasal stuffiness (24%). At the 2-month follow-up visit, the non-users reported frequent nasal stuffiness more often than users (table 4). Nasal problems were reported to be the main reason for cessation by 23% of the patients who stopped the treatment at any time of the study period. Heated humidifiers were given to 42 patients (11%) at the first follow-up or later. These patients did not experience more nasal or pharyngeal symptoms prior to nCPAP. The patients equipped with a humidifier were not more likely to continue treatment at 1 year. There was no seasonal effect on the symptoms.

Discussion

This prospective clinical follow-up of nearly 400 consecutive OSAS patients revealed that nasal and pharyngeal symptoms are common in OSAS patients already before nCPAP treatment. The frequency of upper airway problems seemed not to be associated with the long-term adherence to therapy. The number of patients with most commonly reported symptoms such as dryness of mouth, throat and nose actually decreased during nCPAP treatment.

The frequency of nasal and pharyngeal symptoms before nCPAP treatment is comparable with the results of previous studies performed about 10 years ago [4, 5]. In a retrospective survey, it was reported that nasal and pharyngeal symptoms were frequent in OSAS patients prior to nCPAP, with the most common symptoms being nasal stuffiness, dry nose, sneezing and rhinorrhea [5]. Another and, as far as we know, the only prospective survey conducted before the current study, indicated that over half of the patients suffered from dryness of nose, mouth and throat, sneezing and the sensation of mucus in throat before nCPAP treatment [4]. In our recent analysis of upper airway symptoms in over 500 consecutive patients referred to a diagnostic sleep study, we observed that nasal and pharyngeal symptoms were common in snorers and the frequency of symptoms was related to the severity of sleep apnea [18]. Common clinical experience is that patients start complaining about upper airway symptoms during nCPAP treatment. However, it is important to notice that OSAS patients have nasal and pharyngeal symptoms already before the treatment. We believe that the explanation for this discrepancy is that the patients do not pay enough attention to those symptoms before starting nCPAP treatment.

There are several potential reasons why upper airway problems are common in OSAS patients. Increased nasal airflow resistance may contribute to the development of upper airway obstruction during sleep [19, 20], and several studies have reported snoring and sleep apnea in patients with nasal obstruction [21–23]. Nasal obstruction may be due to different types of rhinitis and anatomical abnormalities, such as nasal polyps and septal deviation. Humidity of inhaled air increases to 80–100% as it passes through the nasal cavity [24]. Although breathing during sleep is normally nasal rather than oral [25], OSAS patients often breathe through the mouth and this may cause dryness of the mouth and throat [26]. Exhalation through the mouth prevents the return of humidity from the lower airways back to the nasal mucosa. Therefore, the nasal and pharyngeal symptoms observed before nCPAP treatment may also be increased by the use of heated humidification [27]. Humidifiers were not used at the time of the previous study. In the present study, heated humidification was added to treatment if the patient complained of persistent and severe upper airway symptoms that could not be managed by local medications.
Although the American Academy of Sleep Medicine has recommended the use of heated humidification as a standard of practice [28], in Finland, it is not routinely given to every patient. In our country, patients get all the equipment related to nCPAP treatment from the public health service, i.e., from the hospital. Humidifiers increase the cost of the treatment and make it slightly more cumbersome. Therefore, humidifiers were not given to the patients before the first follow-up visit after 2 months, and the change in symptoms was not influenced by humidification. Even without humidifiers, the symptoms related to upper airway dryness decreased during nCPAP. Maybe the decrease would have been even greater with humidifiers. In our previous study, the increase in frequency and severity of sneezing and rhinorrhea was more profound in winter [4]. Now, we also analyzed whether there was any seasonal effect on the symptoms and did not find any.

During nCPAP therapy, patients with frequent nasal and pharyngeal symptoms decreased. This symptom alleviation was related to upper airway dryness. Furthermore, the symptom of nasal stuffiness does not always indicate increased nasal airway resistance and is known to be common also in conditions with dry nasal mucosa [29, 30]. Frequent nasal stuffiness decreased in nCPAP users possibly due to diminished dryness of the nasal mucosa as oral breathing decreased during treatment [31].

Long-term adherence to nCPAP was not related to the frequency of upper airway symptoms prior to treatment. This may be due to previous upper airway treatments and lack of severe nasal obstruction. After 2 months, as many as 78% of the patients, and after 1 year, 65% of the patients were continuing with the CPAP treatment. These acceptance rates are similar to the previous studies, which examined long-term CPAP adherence [32, 33]. The hours of use were calculated according to the hours logged by the CPAP devices. The commonly used definition of adequate adherence is the usage of >4 h per night for >70% of days [32–34], which equates to an average use of 2.8 h/night. Of our patients, 58% used the device for >4 h/night and 68% for ≥2.8 h/night. These results are comparable with the adherence rates in previous studies [2, 32–34].

In patients discontinuing nCPAP by 1 year, frequent rhinorrhea had increased significantly at the 2-month follow-up, and nasal stuffiness had become more common among non-users than among users at the 2-month follow-up visit. In a previous study, upper airway symptoms during nCPAP treatment were found to be a significant reason for treatment cessation [4]. In the present study, nasal problems were reported to be the main cause for terminating the treatment by less than one fourth of those who terminated the treatment. In the future, special attention should be paid to those patients suffering from rhinorrhea and nasal stuffiness by offering them humidifiers, different kinds of masks and a consultation with an ENT specialist. Despite frequent symptoms, many of these patients were able to tolerate them and continued nCPAP treatment. Subjective benefit from the nCPAP seemed to be the most important factor determining long-term adherence to the treatment. Almost all of the users (96% after 1 year and 84% after 2 months) benefited from the treatment, whereas <10% of non-users gained any benefit.

We acknowledge some limitations in the present study. First, at our institution, all the patients starting nCPAP are routinely prescribed intranasal steroids, which is a common approach to treat nasal complaints associated with CPAP therapy. Nevertheless, it should be noted that our results are only valid for the CPAP users potentially on intranasal steroids. In a recent study of consecutive OSAS patients initiating CPAP therapy by Ryan et al. [9], it was shown that nasal congestion in patients using fluticasone was significantly less compared with patients receiving dry CPAP treatment, but sneezing and rhinorrhea increased in the fluticasone group. As a result, only one third of the patients were willing to continue with topical steroids after the trial. Overall, it was shown that the addition of a humidifier, but not nasal steroids, decreased nasal symptoms. Second, we did not collect detailed data on the type of mask used by each subject, and therefore, we cannot determine the possible differences in symptom prevalence between patients using different kinds of masks. In our clinic, the mask type is chosen according to the answers to the questionnaire on upper airway symptoms. Full face masks are used in the minority of patients. A full face mask is chosen if a patient reports constant mouth breathing during sleep before starting CPAP or cannot keep the mouth closed during CPAP trials and finds the full face mask more comfortable than the nasal mask.

In conclusion, upper airway symptoms related to mucosal dryness were common in patients with untreated OSAS. Some of the symptoms—dry nose, mouth and throat—actually decreased during nCPAP treatment in patients potentially on intranasal steroids. In patients who terminated the therapy before the 1-year follow-up only rhinorrhea seemed to increase at the first follow-up visit after 2 months of treatment. Frequent upper airway problems before nCPAP start did not predict long-term adherence to the therapy in these consecutive patients of our clinic.